Ämnen: Industri, tillverkning

Farxiga reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

28 Mars 2020 14:20

New data from a sub-analysis of the landmark Phase III DAPA-HF trial showed that AstraZeneca’s Farxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of their background therapy.

Lokelma approved in Japan for the treatment of hyperkalaemia

26 Mars 2020 08:02

AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has been approved in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood).

AstraZeneca to discover and develop siRNA therapeutics for Cardiovascular, Renal, Metabolic and Respiratory diseases in new collaboration

25 Mars 2020 08:20

Collaboration with Silence Therapeutics aims to develop novel, targeted treatments to address significant unmet need
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases.
This multi-target collaboration will harness Silence’s estab

AstraZeneca donerar 9 miljoner ansiktsmasker för att underlätta sjukvårdens hantering av COVID-19 över hela världen

24 Mars 2020 09:08

AstraZeneca donerar nio miljoner ansiktsmasker för att stödja sjukvårdspersonal runt om i världen som hanterar den globala COVID-19 pandemin. Italien kommer få de första sändningarna av andningsmasker redan under denna vecka, och leverans till fler länder följer.

Lynparza granted orphan drug designation in Japan for BRCA-mutated metastatic pancreatic cancer

19 Mars 2020 08:01

AstraZeneca today announced that Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer. Lynparza is co-developed and co-commercialised with MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada)

Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer

17 Mars 2020 08:02

High-level results from the final analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies confirmed a sustained, clinically meaningful overall survival (OS) benefit for patients with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.

Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable, Stage IV bladder cancer

6 Mars 2020 08:02

The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not meet the primary endpoints of improving overall survival (OS) versus standard-of-care (SoC) chemotherapy for Imfinzi monotherapy in patients whose tumour cells and/or tumour-infiltrating immune cells express high levels (≥25%) of PD-L1, or for Imfinzi

AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines

2 Mars 2020 08:01

AstraZeneca today announced that it has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).

AstraZeneca divests global rights to Movantik

25 Februari 2020 08:02

AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC).

AstraZenecas BioVentureHub och IBM samarbetar för att stärka kompetens inom digital hälsa

19 Februari 2020 19:36

AstraZeneca meddelar idag att man ingått ett nytt samarbete med IBM Sverige genom BioVentureHub. Små och medelstora företag (SME) som är anslutna till IBM Sweden eller AstraZenecas BioVentureHub erbjuds nu tillgång till varandras öppna plattform för innovation.

AstraZeneca PLC:s resultatrapport för helåret och fjärde kvartalet 2019

14 Februari 2020 08:10

Ett år präglat av betydande innovation för patienter; den strategiska omvandlingen accelererar 
AstraZeneca har levererat ett år med stark tillväxt, tack vare lanseringen av nya läkemedel, ytterligare framsteg i forskningsportföljen och med ett stort antal godkännanden och övergripande resultat. Dessa trender kommer att fortsätta under 2020, tillsammans med vinsttillväxt och tillväxt i likvida

Anna-Lena Engwall ny marknadsbolagschef för AstraZeneca Nordic-Baltic

29 Januari 2020 08:00

​AstraZeneca meddelar i dag att man har anställt Anna-Lena Engwall som chef för AstraZenecas nordisk-baltiska marknadsbolag, hon tillträder tjänsten den 6 februari 2020.

Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint

27 Januari 2020 08:11

High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca’s and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu, achieved a statistically significant and clinically meaningful improvement in objective response rate and overall survival in patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction cancer.....

Brilinta met primary endpoint in Phase III THALES trial in stroke

27 Januari 2020 08:07

High-level results from the Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone.

AstraZeneca divests rights to established hypertension medicines

27 Januari 2020 08:05

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs)

AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan

27 Januari 2020 08:02

AstraZeneca will recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III programme in Crohn’s disease (CD) and a Phase IIb trial in ulcerative colitis (UC).

AstraZeneca Young Health Programme to partner with UNICEF to prevent non-communicable diseases among young people

22 Januari 2020 10:45

AstraZeneca announced today that it will support UNICEF with a $12.5 million grant to support programming which will reach more than five million young people, train 1,000 youth advocates, and positively shape public policy around the world, over the next six years.

Ny strategi ska eliminera AstraZenecas utsläpp till 2025 och göra hela värdekedjan koldioxidnegativ till 2030

22 Januari 2020 10:28

AstraZeneca presenterade idag ett ambitiöst program för att eliminera koldioxidutsläppen från den globala verksamheten till 2025 och säkerställa att hela värdekedjan är koldioxidnegativ till 2030. Detta innebär att AstraZenecas planer att minska utsläpp av växthusgaser tidigareläggs med mer än ett decennium.

Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer

20 Januari 2020 08:03

​AstraZeneca’s Imfinzi (durvalumab) and tremelimumab,an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.

Lynparza regulatory submission granted Priority Review in the US for HRR-mutated metastatic castration-resistant prostate cancer

20 Januari 2020 08:02

AstraZeneca and MSD today announced that a supplemental New Drug Application for Lynparza has been accepted and granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations, who have progressed following prior treatment with a new hormonal agent.